Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Madalena Tarsounas' group have recently published two new papers in EMBO Molecular Medicine and Nature Communications.

The Tarsounas group, Department of Oncology

In Tacconi et al . they discovered that chlorambucil, an alkylating agent in clinical use for the treatment of leukemia, has a high therapeutic potential against BRCA1/2-mutated tumours. Importantly, while being equally effective as cisplatin against this tumour subset, chlorambucil showed significantly lower overall toxicity.

Find the original publication here:

https://www.embopress.org/lookup/doi/10.15252/emmm.201809982

 

In Reisländer et al. they demonstrated that loss of BRCA2 leads to activation of the cGAS-STING pathway which results in a cell-intrinsic type I interferon response. Importantly, this innate immune response in BRCA2-deficient cells is potentiated by treatment with PARP inhibitors.

Find the original publication here:

https://www.nature.com/articles/s41467-019-11048-5

 

Similar stories

MP Anneliese Dodds tours Oxford cancer research

Anneliese Dodds, MP for Oxford East & Chair of the Labour Party, visited the University of Oxford to learn more about the impactful work happening across departments in the field of cancer research.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana has found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Further funding secured to hunt out cancer using innovative radiotherapy techniques

Initial success leads to new award for Oxford researcher pushing forward new cancer-hunting radiotherapy despite lockdown.

Reprogramming tumour cells using an antimalarial drug

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.